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Abstract Several studies show an association of a guanine for 
adenine substitution (A —> G) at position 3243 in mitochondrial 
DNA (mtDNA) with a recently recognized diabetic subtype 
designated maternally inherited diabetes and deafness (MIDD). 
This mutation shows heterogeneity in its phenotypic expres­
sion as is apparent from its association with several other 
syndromes. Screening for the 3243A —> G mutation in mtDNA 
was performed in those diabetic patients attending the Leiden 
University Hospital diabetics clinic who had a history of ma­
ternally inherited diabetes, sensorineural hearing loss, or both. 
Four individuals from three unrelated families were identified 
who suffered from progressive nondiabetic kidney disease in 
association with diabetes mellitus and hearing loss. The mode 
of inheritance suggested maternal transmission. The combina­
tion of renal failure and hearing loss had been misdiagnosed as 
Alport syndrome in three of the four individuals. Therefore, in 
addition to these three families, another 63 unrelated patients 
with possible Alport syndrome were selected at random. DNA 
from peripheral blood and other tissues from members of the 
three families and from the 63 additional Alport syndrome 
patients was examined for the presence of the 3243A —> G 
mutation in mtDNA. The mutation was detected in heteroplas- 
mic form in the four patients and their maternal relatives. Also, 
one of the 63 suspected Alport syndrome patients showed 
heteroplasmy for the 3243 mutation. These data show the 
existence of a kidney disease that is characterized by the 
presence of the A —> G mutation at position 3243 in the 
mtDNA. (J Am Soc Nephrol 8: 1118-1124, 1997)
Previously, we reported the association of maternally inherited 
diabetes and deafness (MIDD) with a guanine for adenine 
(A —» G) transition at position 3243 in the mitochondrial DNA 
(mtDNA) (1,2). Subsequently, this mutation was identified in 
approximately 1% of diabetic populations in both Europe (3,4) 
and Japan (5,6). Interestingly, the same mutation is also present 
in most patients with the MELAS syndrome (myopathy, en­
cephalopathy, lactic acidosis, and strokelike episodes) (7), in­
dicating a striking phenotypic heterogeneity in expression of 
the mutation. The pathophysiological basis of this phenomenon 
is unknown, but variations in tissue-specific heteroplasmy 
(mixtures of wild-type and mutant mtDNA at a cellular level) 
or effects of the nuclear background have been suggested.
We re-evaluated the type of diabetes in those diabetic pa­
tients in our outpatient department who had a history of ma­
ternally inherited diabetes, sensorineural hearing loss, or both, 
by screening for the presence of the 3243 mutation in mtDNA. 
In four female postrenal transplant patients from three unre-
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lated families, the mutation was found. Remarkably, three of 
them had been diagnosed with Alport syndrome, although 
hematuria had never been present. They developed steroid- 
induced diabetes after kidney transplantation for end-stage 
renal failure. This suggests that primary kidney disease with 
progressive renal failure may represent a third major pheno­
typical expression of the 3243 mtDNA mutation.
Materials and Methods
Screening for the 3243 mtDNA mutation in those diabetic patients 
attending the Leiden University Hospital diabetes clinic who had a 
maternal family history of diabetes, sensorineural hearing loss, or both 
revealed 15 positive individuals from 14 families. Of these, four 
positive female patients from three families had a medical history in 
which kidney disease was predominant and diabetes was only sec­
ondary to steroid treatment after renal transplantation. Their clinical 
characteristics are given below. A detailed family history was re­
corded (Figure 1). Nine family members of these four probands, all in 
the maternal lineage and reported to be free of clinical disease, were 
screened for presence of the mutation, changes in glucose homeosta­
sis, hearing loss, and kidney disease by assessing the ratio of albumin 
to creatinine in a fasting urine sample (8). A complete medical history 
was taken, and blood pressure, height, and weight were measured. A 
urine sediment was examined for the presence of hematuria. After an 
overnight fast, venous blood samples were collected for assessment of 
glucose, glycosylated hemoglobin (HbAlc), and creatinine, and an 
oral 75-g glucose tolerance test was performed.
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Glycosylated hemoglobin (HbAlc) was determined by an HPLC 
method. The normal range for this method is 4.3 to 6.3%. Urinary 
albumin excretion was assessed by methods of a kinetic “rate”- 
nephelometry system (upper limit of normal of <0.019 g/L). Creati­
nine was assessed by an autoanalyzer technique (normal ranges, 70 to 
133 juunol/L [0.8 to 1.5 mg/dl]).
mtDNA Analysis
Total DNA, isolated from peripheral blood, oral mucosa, fibro­
blasts, or kidney, was examined for the presence and the degree of 
heteroplasmy for the mt3243 mutation. This mutation generates an 
Apal restriction site. The region surrounding the tRNALeuiUUR) gene 
mutation was amplified using 32P-labeled nucleotides and subse­
quently digested with Apal. DNA fragments were separated by elec­
trophoresis on polyacrylamide gels, and radioactivity in the fragments 
was quantified by liquid scintillation counting and by quantification 
on a phosphorimager. To examine the possible relationship between 
the three pedigrees, mitochondrial polymorphism at positions 195 and 
16304 was examined by DNA sequence analysis.
Results
The four probands (A-III-4, A-III-2, B-IV-3, and C-IV-3) 
are Caucasian women with a comparable history of disease 
(Table 1). At a mean age of 26 yr (range, 17 to 35 yr), they 
developed hypertension, proteinuria, and a slow progression of 
renal failure, in combination with sensorineural hearing loss, 
the latter most pronounced at high frequencies and necessitat­
ing a healing aid. No hematuria had ever been documented. 
Nevertheless, the diagnosis of Alport syndrome was assumed 
in three cases. After a mean period of 7 yr (range, 3 to 9 yr), 
end-stage renal failure had developed necessitating hemodial­
ysis, and kidney transplantation followed after a mean period
of 4 yr (range, 2 to 6.5 yr). After transplantation and during 
high doses of prednisone, three of them (A-III-4, A-III-2, and 
B-IV-3) developed diabetes mellitus. In the other female car­
rier (C-IV-3), the presence of gestational diabetes was reported 
approximately 7 yr before transplantation, and non-insulin- 
dependent diabetes had become manifest 2 yr before transplan­
tation.
Three years before transplantation, subject A-III-2 under­
went bilateral nephrectomy, which led to the histological di­
agnosis of chronic lobular glomerulonephritis. Renal biopsies 
of patient B-IV-3 and patient C-IV-3 were reported to show 
focal glomerulosclerosis and chronic glomerulosclerosis with 
hyalinized glomeruli, respectively. None of these biopsies was 
available for re-examination.
In addition, because three of the four female patients had 
been diagnosed as having Alport syndrome, DNA from 63 
patients with the clinical diagnosis of Alport syndrome (Uni­
versity Hospital Nijmegen) was screened for the mt 3243 
mutation and found to be positive in one case.
Figure 1 shows the pedigrees of the three families. There is 
no known relation in the maternal lineage between the pedi­
grees. This is underscored by a different mtDNA haplotype;
e.g., pedigree A shows at position 195 a C in homoplasmic 
form, whereas pedigree B exhibits a T. Similarly, at position 
16304, pedigrees A and B have a T and C, respectively.
All nine additional examined maternal relatives were also 
found to be positive for the mutation. Figure 2 shows the 
results of mtDNA analysis in three subjects and a healthy 
control. Proteinuria was found in subject A-IV-7, son of pro­
band A-III-4, and to a lesser extent in the youngest daughter of
Table 1. Characteristics of the examined members of the three families11
Subject13 Sex Age OGTT DM (age at 
onset; therapy)0
Hearing Loss 
(dB)
Serum-Creatinined 
( jjl mol/L)
Urinary 
Albumin to 
Creatinine 
(mg/mmol)
Blood Pressure 
(mmHg)
% Heteroplasmye 
Blood Oral Mucosa
A-III-4 (prob) F 56 DM (38;I) HA RTx (38) AHT 12 21
A-III-2 (prob) F 65 DM (48 ;D) HA RTx (47) AHT 6 15
A-III-3 F 61 N 80 83 0.4 160/84 5 17
A-IV-3 M 35 N 0 92 0.4 130/80 4 4
A-IV-4 M 31 N 0 96 0.5 117/67 13 15
A-IV-5 F 28 N 0 79 0.4 117/79 9 16
A-IV-6 F 25 N 0 73 1.4 110/77 17 30
A-IV-7 M 30 N 45 79 45.5 140/90 20 31
A-IV-8 F 28 N 30 71 0.7 117/90 27 35
A-IV-9 F 26 N 40 68 3.5 120/77 17 30
B-IV-3 (prob) F 34 DM (25 ;0) HA RTx (25) AHT 34 32
C-IV-3 (prob) F 41 DM (34;I) HA RTx (36) AHT 18 32
C-III-1 F 69 N 60 79 1.5 126/70 4 7
"OGTT, oral glucose tolerance test; DM, diabetes mellitus; I, insulin; D, diet; O, oral medication; dB, decibel; prob, proband; F, 
female; HA, hearing aid; RTx, renal transplantation; AHT, antihypertensive treatment; N, normal outcome of OGTT; M, male. 
b Capital letters indicate family, roman numerals generation, and arabic numerals identification number. 
c Age at diagnosis and mode of therapy are given in parentheses, 
d Age at transplantation is given in parentheses.
e % heteroplasmy indicates the percentage of total mitochondrial DNA in the tissue examined harboring the mutation.
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Figure 2. Apal digestion of amplified PCR fragments. (A) Blood (leukocytes). Lane 112, patient A-III-2; lane 67 > patient A-III-4; lane 83, 
patient B-IV-3. (B) Tissue distribution in patient A-III-4. L, leukocyte; OM, oral mucosa; F, fibroblast; C, healthy controL
this proband (A-IV-9) (albumin to creatinine ratio, 45.5 and 3.5 
mg/mmol, respectively). No hematuria was observed. In a 
timed urine sample of subject A-IV-7, total albumin excretion 
rate was found to be 1.5 g/24 h. For this reason, he underwent
renal biopsy, which showed no pathologic alterations at light 
microscopy. Immunofluorescence showed only small quanti­
ties of IgM in mesangial areas of some glomeruli, and no 
deposits of IgG, IgA, C3, and Clq. When examined by electron
1122 Journal of the American Society of Nephrology
microscopy, the glomerular basement membrane showed some gesting that Goodpasture’s antigen was present in both. Th
variation in thickness. The most striking alterations observed patient’s current creatinine clearance rate was 138 ml/min. 
concerned the glomerular visceral epithelial cells, which
showed extensive obliteration of their foot processes (Figure Discussion
3). No electron-dense deposits were found along the glomer- Our data show the presence of an A G transition at
ular capillary walls or in the mesangial areas. Immunofluores- position 3243 in mtDNA in four female patients from three
cence studies using an antibody against Goodpasture’s antigen pedigrees, three of whom were previously thought to have
showed staining of the glomerular basement membrane on both Alport syndrome. So far, this mutation has been described
the kidney of this subject and a healthy control kidney, sug- mainly in association with either MEL AS or MIDD. There are
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Figure 3. Electron microscopic picture of a glomerular capillary wall in renal biopsy of patient A-IV-7. (A) The glomerular basement membrane 
varies somewhat in thickness. The most striking alterations observed concern the glomerular visceral epithelial cells, which show extensive 
obliteration of their foot processes. No electron-dense deposits are found along the glomerular capillary wall and in the mesangial area 
(Magnification, X7700). (B) Higher enlargement illustrating extensive effacement of glomerular visceral epithelial cell foot processes (arrow) 
(Magnification, X 23,100).
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two case histories in which the mutation was found in associ­
ation with kidney disease. Manouvrier et al (9) described a 
family with hypertrophic cardiomyopathy, diabetes mellitus, 
renal failure, and sensorineural deafness. Yorifuji et al (10) 
reported the mutation in a child with growth hormone defi­
ciency, nephropathy, moderate mental retardation, diabetes, 
and facial dysmorphism. The mutation is virtually absent in the 
background population without these syndromes. By chance, 
the finding of three unrelated pedigrees with a kidney disease 
clinically mimicking Alport syndrome, having the 3243 muta­
tion, is extremely unlikely, and its more-than-sporadic occur­
rence indicates an association of the mutation with a new 
syndrome or phenotypical expression. This suggestion was 
further approached independently by screening 63 suspected 
Alport syndrome patients, which demonstrated one additional 
case of the mtDNA mutation.
The patients described in this paper share the characteristics 
of hereditary progressive renal disease and healing loss with 
Alport syndrome, but in retrospect, the absence of hematuria 
and the severity of kidney disease in women are unusual 
features. Also, the glomerular capillary wall abnormality in a 
kidney biopsy from a proteinuric carrier of the mutation differs 
from the histological abnormalities in Alport syndrome.
It should be recognized that the new syndrome we describe 
in this article is only a new phenotypical expression in the 
surprisingly broad clinical spectrum associated with the 
mtDNA 3243 mutation, which is also true in all mtDNA 
diseases, as reviewed recently (11). This might be related to the 
special features of mitochondrial inheritance, including hetero- 
plasmy (mixtures of wild-type and mutant mtDNA at a cellular 
level) and different levels of heteroplasmy in specific tissues. 
The mtDNA 3243 mutation, coding for the mt tRNALeu(UUR), 
causes a defect in the mitochondrial synthesis of proteins 
involved in oxidative phosphorylation and, hence, results in 
diminished ATP production. An indication for the importance 
of the oxidative phosphorylation in renal tissue is also given by 
the description of other mtDNA defects. mtDNA deletions 
have been found in a few patients with Pearson syndrome 
(including tubulopathy), Kearns-Sayre syndrome, and in pa­
tients with chronic tubulointerstitial nephropathy (12-20).
Although the dominant clinical features of MEL AS, MIDD, 
and the above-described new syndrome are different, these mt 
3243 syndromes show some overlap in the concomitant occur­
rence of mild neuromuscular disease, hearing loss, diabetes, 
and renal insufficiency.
In clinical practice, in the case of patients with progressive 
hereditary renal disease and sensorineural hearing loss without 
the characteristic features of Alport disease, one should con­
sider the presence of this mitochondrial kidney disease. 
Screening for the mt 3243 mutation in patients with Alport-like 
clinical manifestations is relatively easy. This might be impor­
tant in genetic counseling, to eliminate X-linked transmission 
of the disease, as in classic Alport syndrome. The prevalence of 
the above-described new syndrome, its pathophysiology and 
natural history, and the clinical penetrance of renal disease in 
earners of the mt 3243 mutation have yet to be established.
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